Whilst small-depend MBL almost never progresses to CLL, superior-rely MBL progresses to CLL necessitating therapy at a charge of 1% to 2% a year. Significant-count MBL is distinguished from Rai 0 CLL depending on if the B-cell rely is over or under 5 × 109/L. Though people with equally higher-count MBL and CLL Rai phase 0 are at improved threat of